APBDRF

Feedback: 12TH ANNUAL SCIENTIFIC ADVISORY BOARD MEETING

| How are you connected to APBDRF? (Check all that apply) | ☐ Research Scientist on APBD | | | |
|----------------------------------------------------------------------------------------|----------------------------------------------------------------|--|--|--|
| | ☐ Research Scientist on related disease/disease mechanism | | | |
| | ☐ Physician | | | |
| | ☐ Other Health profession (e.g. genetics, clinical, lab, etc.) | | | |
| | ☐ Patient/family member | | | |
| | ☐ Friend/supporter | | | |
| | ☐ APBDRF staff/adviser | | | |
| | ☐ Other: | | | |
| | | | | |
| | | | | |
| Overall what aspects of t | he conference were most interesting and valuable to you? | | | |
| Overall, what aspects of the conference were most interesting and valuable to you? | | | | |
| ☐ The quality, content and findings of presentations | | | | |
| ☐ Opportunity to talk/meet directly with researchers/colleagues | | | | |
| ☐ Opportunity to learn about the range of research underway | | | | |
| ☐ Hopeful implications of the research – the potential promise for a treatment or cure | | | | |
| ☐ Other: | | | | |

| Overall, how would you rate the conference? | | | | | | | | |
|---------------------------------------------|---|----|---|---|-----------|---|--|--|
| Poor | | Ok | | | Excellent | | | |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | | |

| Which of the sessions (presenter/moderator) did you attend? (check those you attended) | | | | | |
|-----------------------------------------------------------------------------------------|-----------------------------------------|--|--|--|--|
| Monday | | | | | |
| 1. GBE Stabilization (Various presenters) | | | | | |
| 2. Genetic Interventins (Various) | | | | | |
| 3. MyJewishGenetics (Schreiber-Agus) | | | | | |
| 4. Duke GSD IV (Kishnani, Sun) | | | | | |
| 5. Triheptanoin (Schiffmann) | | | | | |
| 6. Proposed guaiacol trial (Kakhlon) | | | | | |
| 7. Clinical Endpoint discussion (various) | | | | | |
| 8. High Throughput Screening (Kakhlon) | | | | | |
| 9. Life Through a Lens (Screening, Zuckerman) | | | | | |
| Tuesday | | | | | |
| 10. Repurposed Drug Initiatives (Bloom, various) | | | | | |
| a. Guaiacol (Kakhlon) | | | | | |
| b. Recombinant Glycogen Synthase (Kakhlon | /Yue)□ | | | | |
| c. Ibudilast/gualfenesin (Akman) | | | | | |
| d. Pharmacophore-based small molecules (K | akhlon) □ | | | | |
| 11. Genetic Testing, Natural History Studies, Bioba | | | | | |
| a. (Correia) | | | | | |
| b. Patient Registry (Schiffmann) | | | | | |
| c. Genetic Testing (Kornreich) | | | | | |
| d. Carrier screening advances (Cecchi) | | | | | |
| e. Natural History Studies, NORD (Rossov) | | | | | |
| f. Orphan Products-Natural Hist. (Jones) | | | | | |
| | | | | | |
| g. Biobank of fibroblasts (Kakhlon) | _ | | | | |
| | | | | | |
| Which of the above sessions did you find most interes | sting/informative? Most understandable, | | | | |
| clearest? Most promising to pursue further? Please I | ist top choices in each category, by | | | | |
| number and letter (from above listing): | | | | | |
| Informative/interesting Clear/understandable Promising | | | | | |
| 1 | | | | | |
| 2 | | | | | |
| 3 | | | | | |
| 4. | | | | | |
| | | | | | |
| | | | | | |
| Do any of the treatment annuach as presented stand | out as most urgent for the APRORE to | | | | |
| Do any of the treatment approaches presented stand out as most urgent for the APBDRF to | | | | | |
| press forward with support, and if so, which one? | | | | | |

What improvements/changes would you recommend for future conferences (other than A/V technology?) Please provide us your candid comments or recommendations.